DCT

1:26-cv-06553

Novo Nordisk Inc v. Apotex Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-06553, D.N.J., 06/04/2026
  • Venue Allegations: Venue is alleged to be proper as Defendant Apotex is a foreign corporation and because it conducts business in New Jersey, has previously consented to jurisdiction in the district, and intends to market and sell the accused product in New Jersey.
  • Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's WEGOVY® (semaglutide) tablets infringes seven U.S. patents covering the drug's composition, formulation, and methods of use.
  • Technical Context: The lawsuit concerns oral formulations of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, a class of drugs previously administered primarily via injection.
  • Key Procedural History: The complaint notes that the asserted patents are also the subject of another pending litigation between the same parties in the District of New Jersey, Novo Nordisk Inc. et al. v. Apotex Inc., No. 24-9729-RMB-AMD (D.N.J.) (consolidated). This indicates an ongoing and broader dispute over the same intellectual property.

Case Timeline

Date Event
2010-12-16 Earliest Priority Date for '123 and '957 Patents
2012-06-21 Earliest Priority Date for '499 Patent
2013-05-02 Earliest Priority Date for '923 and '739 Patents
2016-03-08 '123 Patent Issued
2018-02-02 Earliest Priority Date for '248 and '953 Patents
2019-05-07 '923 Patent Issued
2021-06-15 '499 Patent Issued
2022-07-12 '957 Patent Issued
2023-12-05 '248 Patent Issued
2025-03-04 '739 Patent Issued
2025-08-26 '953 Patent Issued
2026-04-29 Plaintiff receives notice of Defendant's ANDA filing
2026-06-04 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,278,123 - "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid," Issued March 8, 2016

The Invention Explained

  • Problem Addressed: The patent addresses the significant challenge of administering peptide and protein drugs, such as GLP-1 agonists, via the oral route due to enzymatic degradation in the gastrointestinal tract and poor absorption through the intestinal mucosa '123 Patent, background section
  • The Patented Solution: The invention is a solid pharmaceutical composition for oral administration that combines a GLP-1 agonist with an absorption enhancer, specifically a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (SNAC) '123 Patent, abstract This combination is designed to protect the peptide from degradation and facilitate its absorption into the bloodstream '123 Patent, col. 11:21-31
  • Technical Importance: This technology represents a method to convert an injectable biologic drug into an oral tablet, a major goal in pharmaceutical development sought for improving patient convenience and compliance.

Key Claims at a Glance

  • The complaint asserts dependent claim 9, which relies on independent claim 1 Compl. ¶61
  • The essential elements of independent claim 1 and dependent claim 9 are:
    • A solid composition for oral administration, comprising:
    • a GLP-1 agonist,
    • a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (SNAC), and
    • at least one excipient selected from the group consisting of a lubricant, binder, and filler;
    • wherein the GLP-1 agonist is semaglutide (added by claim 9); and
    • wherein the composition comprises at least 60% (w/w) of said salt of SNAC (added by claim 9).
  • The complaint reserves the right to assert other claims Compl. ¶21

U.S. Patent No. 10,278,923 - "Oral Dosing of GLP-1 Compounds," Issued May 7, 2019

The Invention Explained

  • Problem Addressed: The patent background notes the general difficulty of oral peptide administration and highlights a need for improved methods that provide acceptable variability in plasma concentration '923 Patent, col. 1:21-33
  • The Patented Solution: The invention is a method of treatment using a specific oral dosing regimen for a long-acting GLP-1 peptide. It claims that administering the peptide more frequently than its long half-life would suggest (e.g., daily dosing for a peptide with a multi-day half-life) surprisingly reduces the variability in its plasma concentration '923 Patent, col. 2:34-45 The patent claims a method where the ratio of the peptide's plasma half-life (in days) to the dosing interval (in days) is greater than 2:1 '923 Patent, claim 14
  • Technical Importance: Reducing inter-patient and intra-patient variability in drug exposure can lead to more predictable therapeutic effects and a better safety profile, which is critical for chronically administered drugs.

Key Claims at a Glance

  • The complaint asserts independent claim 14 Compl. ¶86
  • The essential elements of independent claim 14 are:
    • A method for treating diabetes and/or obesity in a subject, comprising:
    • orally administering to said subject a therapeutically effective amount of a solid oral dosage form composition comprising:
    • a GLP-1 peptide from a group including semaglutide and having a plasma half-life in humans of at least 60 hours, and
    • an enhancer that is a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (SNAC);
    • wherein the composition is administered such that the ratio between the plasma half-life in days of the peptide and the dosing interval in days is more than 2:1.
  • The complaint reserves the right to assert other claims Compl. ¶22

U.S. Patent No. 11,033,499 - "Tablet Formulation Comprising a GLP-1 Peptide and a Delivery Agent," Issued June 15, 2021

  • Patent Identification: U.S. Patent No. 11,033,499, "Tablet Formulation Comprising a GLP-1 Peptide and a Delivery Agent," Issued June 15, 2021 Compl. ¶34
  • Technology Synopsis: This patent claims a tablet with specific physical characteristics. It addresses the problem of achieving sufficient bioavailability for oral peptides by defining properties like bulk density, pore diameter, crushing strength, and disintegration time, which are disclosed to be critical for optimal drug release and absorption '499 Patent, abstract '499 Patent, col. 3:3-10
  • Asserted Claims: At least claim 1 Compl. ¶109
  • Accused Features: The physical properties of Apotex's proposed generic tablet, which are alleged to be identical or substantially identical to those of WEGOVY® tablets Compl. ¶¶106-108

U.S. Patent No. 11,382,957 - "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid," Issued July 12, 2022

  • Patent Identification: U.S. Patent No. 11,382,957, "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-hydroxybenzoyl)Amino)Caprylic Acid," Issued July 12, 2022 Compl. ¶37
  • Technology Synopsis: This patent, similar to the '123 Patent, claims a solid oral composition containing semaglutide and a high concentration (at least 60% w/w) of a SNAC salt. It further specifies the presence of at least one excipient from the group of a lubricant, binder, or filler '957 Patent, claim 1 This patent appears to be a continuation of the '123 patent family, further securing the core formulation.
  • Asserted Claims: At least claim 1 Compl. ¶131
  • Accused Features: The formulation of Apotex's proposed generic product, which is alleged to contain semaglutide, a salt of SNAC, and an excipient (magnesium stearate) in the claimed proportions (Compl. ¶¶124; Compl. ¶128).

U.S. Patent No. 11,833,248 - "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid," Issued December 5, 2023

  • Patent Identification: U.S. Patent No. 11,833,248, "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-hydroxybenzoyl)Amino)Caprylic Acid," Issued December 5, 2023 Compl. ¶40
  • Technology Synopsis: This patent claims a very specific formulation "consisting essentially of" semaglutide, magnesium stearate, and SNAC. The "consisting essentially of" language is intended to exclude other ingredients, such as binders or fillers, that would materially affect the invention's properties. It also claims a specific ratio of magnesium stearate to SNAC '248 Patent, claim 1
  • Asserted Claims: At least claim 1 Compl. ¶154
  • Accused Features: The minimalist formulation of Apotex's proposed product, which is alleged to contain only semaglutide, SNAC, and magnesium stearate, thereby infringing the restrictive "consisting essentially of" claim (Compl. ¶¶147; Compl. ¶151).

U.S. Patent No. 12,239,739 - "Oral Dosing of GLP-1 Compounds," Issued March 4, 2025

  • Patent Identification: U.S. Patent No. 12,239,739, "Oral Dosing of GLP-1 Compounds," Issued March 4, 2025 Compl. ¶43
  • Technology Synopsis: This patent claims a method for treating type 2 diabetes or reducing body weight by administering a composition of semaglutide and SNAC daily for 70 days. The key feature is the reduction in variability of plasma exposure compared to a single dose '739 Patent, claim 1 This is related to the '923 Patent but specifies a particular duration and outcome.
  • Asserted Claims: At least claim 1 Compl. ¶179
  • Accused Features: The instructions on Apotex's proposed label, which allegedly direct daily administration for treating obesity, thereby inducing infringement of the claimed method Compl. ¶¶170-172 Compl. ¶176

U.S. Patent No. 12,396,953 - "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid," Issued August 26, 2025

  • Patent Identification: U.S. Patent No. 12,396,953, "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-hydroxybenzoyl)Amino)Caprylic Acid," Issued August 26, 2025 Compl. ¶46
  • Technology Synopsis: This patent claims a composition comprising semaglutide, SNAC, and magnesium stearate, with specific concentration ranges for the components. A key limitation is that the SNAC constitutes at least 95% (w/w) of the total excipients, suggesting an invention focused on a highly pure formulation where SNAC is the dominant non-active ingredient '953 Patent, claim 1
  • Asserted Claims: At least claim 1 Compl. ¶202
  • Accused Features: The alleged composition of Apotex's product, which is purported to have a formulation where SNAC is the primary excipient, matching the patent's high-purity requirement (Compl. ¶¶195; Compl. ¶199).

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Apotex's ANDA Product, a proposed generic version of Novo Nordisk's WEGOVY® (semaglutide) tablets in 1.5 mg, 4 mg, and 9 mg dosage strengths for oral administration Compl. ¶14

Functionality and Market Context

  • The complaint alleges that the accused product is a solid oral tablet containing the GLP-1 receptor agonist semaglutide as the active ingredient (Compl. ¶¶14; Compl. ¶54). Its purpose is to treat obesity and reduce cardiovascular risk by mimicking the effects of the natural GLP-1 hormone Compl. ¶8 The complaint alleges that Apotex's product is intended to be a lower-cost, bioequivalent substitute for WEGOVY® tablets, and that its proposed labeling and composition will essentially copy Novo Nordisk's brand-name product (Compl. ¶¶16; Compl. ¶58). The complaint includes a visual representation of the chemical structure of semaglutide, the active ingredient in both WEGOVY® and the accused product Compl. p. 4, Figure 1

IV. Analysis of Infringement Allegations

'123 Patent Infringement Allegations

Claim Element (from Independent Claim 1 and Dependent Claim 9) Alleged Infringing Functionality Complaint Citation Patent Citation
A solid composition for oral administration... Apotex's ANDA Product is described as tablets for oral use. ¶14 col. 12:40-44
...comprising a GLP-1 agonist... The active ingredient in Apotex's ANDA Product is semaglutide, a GLP-1 agonist. ¶54 col. 11:7-11
...wherein the GLP-1 agonist is semaglutide... The active ingredient is identified as semaglutide. ¶54 col. 11:43-49
...a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid... Apotex's product contains the inactive ingredient salcaprozate sodium (SNAC), which is a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. ¶54 col. 11:51-53
...and at least one excipient selected from the group consisting of a lubricant, binder, and filler... Apotex's product contains magnesium stearate, which is a lubricant. ¶54 col. 12:59-62
...wherein the composition comprises at least 60% (w/w) of said salt... The complaint alleges Apotex's ANDA product is identical or substantially identical to the WEGOVY® tablet composition, which is covered by claim 9. ¶58 col. 12:20-24

'923 Patent Infringement Allegations

Claim Element (from Independent Claim 14) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for treating diabetes and/or obesity... The proposed label for Apotex's product allegedly instructs its use for reducing excess body weight in adults with obesity or overweight. ¶78 col. 3:42-45
...comprising orally administering to said subject a therapeutically effective amount of a solid oral dosage form composition... The product is an oral tablet to be administered once daily. ¶77 col. 2:10-14
...comprising a GLP-1 peptide that is from a group including semaglutide and has a plasma half-life in humans of at least 60 hours... The active ingredient is semaglutide, which the WEGOVY® label states has a half-life of approximately one week (168 hours). ¶76; ¶80 col. 2:14-16; col. 5:29-33
...an enhancer that is a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid... The product contains salcaprozate sodium (SNAC) as an inactive ingredient. ¶76 col. 2:10-14
...wherein the composition is administered such that the ratio between the plasma half-life in days...of the GLP-1 peptide and the dosing interval in days...is more than 2:1. The alleged half-life is ~7 days and the instructed dosing interval is 1 day (once daily). The resulting ratio is 7:1, which is greater than 2:1. ¶77; ¶80 col. 5:26-34
  • Identified Points of Contention:
    • Scope and Factual Questions ('123 Patent): The infringement analysis for the '123 Patent will likely focus on factual evidence. A key question for the court will be whether Apotex's proposed product, on a weight-for-weight basis, actually contains "at least 60% (w/w)" of the SNAC salt as required by claim 9. While the complaint alleges the product is "identical or substantially identical" Compl. ¶58, this quantitative limitation will be a primary point of factual dispute and discovery.
    • Claim Construction and Method Claim Enforceability ('923 Patent): For the '923 Patent, a central issue may be the construction of "plasma half-life in humans." The analysis will question what evidence is required to establish this value and whether Apotex is bound by the data for Novo Nordisk's WEGOVY®. A second key legal question is one of enforceability: does instructing a "once daily" administration Compl. ¶77 on a product label for a drug with a one-week half-life Compl. ¶80 constitute inducement to infringe a claim defined by a mathematical ratio?

V. Key Claim Terms for Construction

For the '123 Patent

  • The Term: "at least 60% (w/w) of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid"
  • Context and Importance: This quantitative limitation is the core distinguishing feature of asserted claim 9. The infringement analysis will turn on whether Apotex's product meets this specific threshold. Practitioners may focus on this term because it is a precise numerical value that is either met or not, making it a clear target for non-infringement arguments.
  • Intrinsic Evidence for Interpretation: The patent itself provides the primary context.
    • Evidence for a Broader Interpretation: The claim language itself is straightforward. The specification may provide examples of formulations that meet this threshold, which could be used to argue that any formulation meeting the number infringes, regardless of other properties '123 Patent, col. 12:20-24
    • Evidence for a Narrower Interpretation: An accused infringer might argue that this limitation should be read in the context of the specific examples provided in the patent, suggesting that the term implies not just the percentage but also the functional result achieved in those examples '123 Patent, e.g., Table 1

For the '923 Patent

  • The Term: "the ratio between the plasma half-life in days in humans of the GLP-1 peptide and the dosing interval in days of said composition is more than 2:1"
  • Context and Importance: This ratio is the central inventive concept of the claimed method. Its construction will be dispositive for infringement. Practitioners may focus on this term because it links a property of the drug substance ("plasma half-life") to an instruction for its use ("dosing interval"), raising questions about how each component is defined and proven.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent broadly defines "plasma half-life" as the time to halve the plasma concentration after administration and provides a general method for its determination '923 Patent, col. 3:38-41 '923 Patent, col. 6:31-59 This supports an argument that any standard measurement confirming the half-life and any label instruction defining the interval can be used to calculate the ratio.
    • Evidence for a Narrower Interpretation: The specification provides a specific example calculation: "Thus, when the plasma half-life of said GLP-1 peptide is e.g. 2 days in humans the dosing interval in days of said peptide is 1 or less" '923 Patent, col. 6:1-3 A defendant might argue that the term requires the specific calculation methodology and context disclosed, rather than any theoretical calculation.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced and contributory infringement of the method claims (e.g., in the '923 and '739 patents) Compl. ¶¶87 Compl. ¶180 The basis for these allegations is that Apotex's ANDA and its proposed product label will instruct, encourage, and recommend that physicians and patients administer the generic product in a manner that directly practices the steps of the patented methods, such as the specific dosing regimens Compl. ¶¶83-84 Compl. ¶176-177 The complaint also alleges the product has no substantial non-infringing uses Compl. ¶¶85 Compl. ¶178
  • Willful Infringement: While the complaint does not use the word "willful," it lays the groundwork for such a claim by alleging that Apotex has "actual knowledge" of the asserted patents, citing their listing in the FDA's Orange Book Compl. ¶¶52 Compl. ¶75 Compl. ¶100 The complaint further states that Apotex's infringement is exceptional and seeks an award of attorneys' fees under 35 U.S.C. § 285, a remedy often associated with findings of willful infringement Compl. ¶¶69 Compl. ¶94 Compl. ¶116

VII. Analyst's Conclusion: Key Questions for the Case

  • A central factual question will be one of compositional identity: across a "thicket" of seven patents with overlapping and highly specific claims, can Apotex demonstrate that its proposed generic product avoids infringing at least one claim from each patent? This will involve a granular, element-by-element comparison of Apotex's formulation and physical tablet characteristics against numerous patent limitations, such as the precise weight percentage of SNAC, the exclusion of binders, and specific tablet porosity metrics.
  • A key legal question will be one of induced infringement for method claims: Does instructing a "once daily" administration on a product label for a drug with a well-established one-week half-life constitute sufficient affirmative action to find inducement of a method claim defined by a mathematical ratio of half-life to dosing interval? The court's interpretation of the requirements for proving specific intent to encourage infringement in the context of an ANDA "skinny label" strategy will be critical.
  • A core validity question will concern obviousness-type double patenting and obviousness: Given the multiple, closely related patents-in-suit filed over several years, the case will likely examine whether the claims of the later patents are patentably distinct from those of the earlier patents. The court will need to determine if each successive patent, such as those claiming specific physical properties ('499 Patent) or minimalist formulations ('248 Patent), represents a non-obvious improvement over the foundational oral semaglutide-SNAC compositions.
Loading Complaint